Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer, a single arm phase II study. Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, January 03, 2012

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer, a single arm phase II study.



Abstract

The purpose of the current phase II single-arm clinical trial was to evaluate whether pre-treatment with low-dose cyclophosphamide improves immunogenicity of a p53-synthetic long peptide (SLP) vaccine in patients with recurrent ovarian cancer. Ovarian cancer patients with elevated serum levels of CA-125 after primary treatment were immunized four times with the p53-SLP vaccine.........The outcome of this phase II trial warrants new studies on the use of low-dose cyclophosphamide to potentiate the immunogenicity of the p53-SLP vaccine, or other anti-tumor vaccines.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.